Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch to boosted darunavir + dolutegravir in virologically suppressed HIV
NL-OMON41798Withdrawn
- Sponsor
- OLVG
- Start
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of darunavir, ritonavir and dolutegravir in human immunodeficiency virus infection (HIV), sponsored by OLVG. Primary endpoint: Change in quality of life. Planned start Apr 2016; status: withdrawn.
02
Drugs
darunavirritonavirdolutegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NL-OMON41798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41798.